NIPH Clinical Trials Search

UMIN ID: C000000363

Registered date:14/05/2007

A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedIgA nephropathy in children
Date of first enrollment2001/08/01
Target sample size80
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)prednisolone+mizoribine for 2 years prednisolone+mizoribine+warfarin+dipyridamole for 2 years


Primary OutcomeDisappearance rate of proteinuria
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum2years-old
Age maximum18years-old
GenderMale and Female
Include criteria
Exclude criteria1.Systemic diseases defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus, etc) 2.Medical history of allergy or hypersensitivity reactions to prednisolone, mizoribine, warfarin or dipyridamole 3.Chronic renal dysfunction 4.Active infectious disease 5.Severe liver disfunction 6.History of corticosteroid and immunosupressive drug use 7.Pregnancy 8.Judged inappropriate for this study by the physicians

Related Information


public contact
Address Japan
Telephone 073-441-633
Affiliation The Japanese Pediatric IgA Nephropathy of Department of Pediatrics, Wakayama Medical University
scientific contact
Name Norishige Yoshikawa
Address 811-1 Kimiidera Wakayama City Wakayama Japan
Affiliation Wakayama Medical University Department of Pediatrics